Glucagon-like peptide-1 and myocardial protection: more than glycemic control.
Pharmacologic intervention for the failing heart has traditionally targeted neurohormonal activation and ventricular remodeling associated with cardiac dysfunction. Despite the multitude of agents available for the treatment of heart failure, it remains a highly prevalent clinical syndrome with substantial morbidity and mortality, necessitating alternative strategies of targeted management. One such area of interest is the ability to modulate myocardial glucose uptake and its impact on cardioprotection. Glucose-insulin-potassium (GIK) infusions have been studied for decades, with conflicting results regarding benefit in acute myocardial infarction. Based on the same concepts, glucagon-like peptide-1-[7-36] amide (GLP-1) has recently been demonstrated to be a more effective alternative in left ventricular (LV) systolic dysfunction. This paper provides a review on the current evidence supporting the use of GLP-1 in both animal models and humans with ischemic and nonischemic cardiomyopathy.
Fields
Anjali V
AV
Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Patterson
Brandy
B
Karnik
Ankur A
AA
Shannon
Richard P
RP
D000818:Animals; D002311:Cardiomyopathy, Dilated / Q000188:drug therapy; D004195:Disease Models, Animal; D052216:Glucagon-Like Peptide 1 / Q000627:therapeutic use*; D005947:Glucose / Q000378:metabolism*; D006439:Hemodynamics; D006801:Humans; D054795:Incretins / Q000627:therapeutic use*; D017202:Myocardial Ischemia / Q000188:drug therapy; D009206:Myocardium / Q000378:metabolism; D013318:Stroke Volume / Q000187:drug effects; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy*; D016277:Ventricular Function, Left / Q000187:drug effects
D054795:Incretins; D052216:Glucagon-Like Peptide 1; D005947:Glucose